NCT07105228

Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 290,000 (actual)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will describe and estimate the incidence of Retinal Vasculitis (RV) events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea®, aflibercept 2mg) therapy in US clinical practice. The main objective is to describe demographic and clinical characteristics of patients receiving aflibercept 2mg injections, to estimate the incidence of RV and RV plus Intraocular Inflammation (IOI) following aflibercept 2mg injections and to describe characteristics of RV cases.

Detailed description

This study is purely descriptive using US claims data from Komodo Healthcare Map.

Conditions

• Retinal Vasculitis

Interventions

Type	Name	Description
DRUG	aflibercept 2mg	No study-specific interventions administered in this observational study

Timeline

• Start date: 2025-07-15
• Primary completion: 2025-08-30
• Completion: 2025-09-15
• First posted: 2025-08-05
• Last updated: 2025-10-10

Locations

1 site across 1 country: United States